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ABSTRACT 
Association of the Major Histocompatibility Complex 
with Autism 
by 
Wayne W. Daniels, Master of Science 
Utah State University, 1996 
Major Professor: Dr. Reed P. Warren 
Department: Biology 
The pathogenesis of autism has proven difficult to 
characterize. However, in many recent studies, it is 
suggested that the onset of this disorder is the result of 
multiple etiological factors, which include genetic, 
immunologic, and viral elements. 
Possible immunological influences found in 
subpopulations of patients with autism include decreased 
lymphocyte responsiveness, reduced natural killer cell 
activity, abnormal .response to rubella vaccine, abnormal 
iii 
immune response to brain tissue, and decreased plasma levels 
of the fourth component of complement(C4). These aberrations 
and others imply a possible autoimmune mechanism in some 
cases for the development of autism. 
C4 deficiencies have been found in subjects with 
established autoimmune disorders, such as systemic lupus 
erythematosus and chronic active hepatitis, in recent 
investigations. There is also evidence that the major 
histocompatibility genes play an intimate role in autoimmune 
processes. Therefore, in knowing that the C4 genes are 
closely linked to the major histocompatibility genes, this 
study determined and analyzed the human leukocyte antigen 
profile of autistic patients, their siblings, and parents. 
iv 
In this study, it was found that the C4B complement null 
allele occurred in autistic patients at nearly twice the 
frequency compared to normals. However, the C4A complement 
null allele frequency was not found to be significantly 
altered. Several extended haplotypes were represented within 
the patients studied. However, the extended haplotype B44-
SC30-DR4 was the only one found at a significantly increased 
frequency. Further investigations are needed to better 
understand the significance of these findings. 
(64 pages) 
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CHAPTER I 
INTRODUCTION 
Autism is a developmental disorder characterized by 
impaired social development and limited communication skills. 
A definitive etiological agent for this disorder has not yet 
been established; however, the pathogenesis of autism is 
likely a result of multiple factors based upon genetic, 
immunologic, and viral mechanisms. Some recent 
investigations suggest that autism demonstrates several 
features characteristic of established autoimmune disorders, 
such as genetic predipostion,l presence of antibodies against 
brain antigens,2,J,4 sex differencess (autism is four to five 
times more common in boys than in girls), and other immune 
abnormalities. 
Many genes whose products are involved in various immune 
responses are found within the major histocompatibility 
complex (MHC) located on the short arm of the sixth human 
chromosome. The combination of genes found within the MHC is 
referred to as an MHC haplotype. Interestingly, it has been 
found that within the MHC, crossing over occurs at a reduced 
frequency, resulting in haplotypes remaining unchanged for 
many generations. A haplotype exhibiting this behavior has 
been termed an extended haplotype.6 
In Caucasians, extended haplotypes make up approximately 
25-30% of all MHC haplotypes and are of importance because 
they are associated with various clinical manifestations. 
For example, the extended haplotype HLAB*8, BF*S, C2*C, 
C4A*QO, C4B*l, HLADR*3, abbreviated B8-SC01-DR3, is strongly 
associated with systemic lupus erythematosus (SLE) .1 The 
actual pathogenic relationship between B8-SC01-DR3 and SLE 
remains obscure but a plausible explanation for this 
association may be the presence of a null allele at the C4A 
gene of this extended haplotype. A null allele is 
functionally silent (yields no functional gene product) and 
therefore results in reduced plasma levels of C4 protein. 
This C4 deficiency may hinder various complement functions 
including the capacity to prevent the precipitation, or 
proper clearing, of immune complexes. 
Immune abnormalities have also been reported to be 
associated with the C4B locus. For instance, high anti-
cytomegalovirus antibody titers (IgG isotype) have been 
observed in patients with reduced C4B plasma levels.a 
Moreover, persons carrying two null alleles at the C4B loci 
have an increased number of infections of bacterial 
meningitis9 and with Streptococcus pneumoniae, Haemophilus 
influenzae, and Neisseria meningitidis infections.1o 
Low levels of complement C4 protein have been found in 
autistic subjects.ll In addition, an increased frequency of 
the extended haplotype B44-SC30-DR4, which contains a C4B 
null allele, has been reported in the same autistic group.12 
In other studies, possible viral associations have been found 
2 
between autism and rubella or cytomegalovirus infections.13,14 
Many autistic children frequently lacked rubella antibodies 
in spite of previous vaccinations.1s These investigations 
suggest something is awry in the immune system of autistic 
children. Therefore, an investigation of immune mechanisms 
and their possible relationship to autism seems worthwhile. 
3 
AUTISM 
CHAPTER II 
LITERATURE REVIEW 
Autism is a developmental disorder that occurs at a 
frequency of two to five cases per 10,000 individuals with 
the rates of the disorder four to five times higher in males 
than females.16 An estimated 75% of autistic individuals 
function within a retarded range.17 The incidence of births 
of children with autism appears to be seasonal, _peaking 
mostly in March .1e, 19, 2o, 21 The existence of seasonal 
flucuations suggests the involvment of an infectious agent, 
such as a virus, which often causes epidemics during winter 
months, as a potential etiological factor in some cases of 
autism. Persons diagnosed with autism appear to have normal 
life spans and normal physical appearance. Early diagnosis 
.of autism is -important : because the child may begin treatment 
before his or her condition has deviated too far from normal. 
However, diagnosis of autism before the age_ of 12 months is 
difficult because no signs indicate the presence of autism 
during infancy. By definition, the onset of autism must 
occur before the child completes his or her third birthday.l6 
There are three types of behavioral symptoms observed in 
autistic children. These symptoms form the principal 
4 
criteria used in the diagnosis of autism22 and are classified 
as the following categories: 
1. Abnormal development of social relationships. 
There is wide variation in the degree of expression of each 
behavioral symptom depending on the severity of the disorder 
and the age of the patient . Consequently, a symptom 
exhibited in one child may differ markedly in another. An 
autistic child encounters difficulty entering into and 
maintaining normal relationships with other people. He or 
she may treat people as inanimate objects, often unaware or 
unresponsive to feelings or emotions of others. For example, 
an autistic child's mother may be injured and in great pain. 
The child will observe the mother's reaction without any 
emotional response at all, as if he is bewildered and 
confused by the mother's conduct. 
2. Impairment of eommunication. Many children with 
autism do not develop a useful form of speech (i.e. they do 
not produce sounds of recognizable words) . Many of those who 
do achieve well developed speech have other speech 
abnormalities. These abnormalities may include echolalia in 
which the child repeats a word or phrase spoken by another 
person or uses neologisms, words that have a specific meaning 
not understood or used by others. Also, children with autism 
do not appear to use, to be aware of, or to interpret non-
5 
verbal forms of communication .such as facial expressions, 
gestures, eye-to-eye contact, etc. 
3. Child's interests and activities are restricted 
and repetitive. Autistic children show to some degree an 
obsession with the maintenance of sameness. Variations of 
routine activities or environment may greatly disturb the 
child, who usually responds to the change with some sort of 
tantrum. For instance, one child has violent tantrums if his 
mother puts on a new dress, making it necessary for her to 
purchase many dresses of the same color and pattern so as to 
"keep the peace." Another autistic child makes straight long 
lines of bricks for hours, lining the bricks up in exactly 
the same way and in the same precise sequence of colors. 
GENETIC FACTORS IN AUTISM 
Bolton and Rutter have suggested that most cases of 
autism include some underlying genetic factor.23 This 
estimate is supported by two twin studies carried out in 
different countries, England and Norway. The English study24 
found a 36% concordance rate for autism in monozygotic twins 
versus a 0% concordance rate in dizygotic twins. The second 
study2s reported an amazing 89% and 0% concordance rate for 
autism in monozygotic and dizygotic twins, respectively. 
These results strongly suggest that a significant genetic 
influence exists. 
6 
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Ritvo et al.26 studied 46 families with multiple 
incidences of autism and found evidence for an autosomal 
recessive form of inheritance. The same workers later 
completed an epidemiological study27 that revealed a 215 times 
greater chance of a person having autism if he or she is a 
sibling of a child with autism. It is thus evident that the 
etiology of many cases of autism is genetically based. 
AUTISM AS AN AUTOIMMUNE 
DISORDER 
Efforts in understanding the etiology of autoimmune 
diseases have proven to be formidable. However, despite a 
lack of thorough understanding of this phenomenon, a genetic 
influence is suspected in autoimmunity. This suspicion is 
_based on findings of multiple incidence of an autoimmune 
disease within a family. Interestingly, Money et a1.2a 
reported a case of a child with autism and an autoimmune 
disease, Addison's disease (this child also had moniliasis). 
Moreover, two older brothers exhibited various clinical 
conditions including hypoparathyroidism, Addison's disease, 
moniliasis, and alopecia totalis. A third brother and 
parents were healthy and asymptomatic of any identifiable 
disease condition. The authors concluded that the autistic 
state might have been attributed to autoantibodies in some 
way affecting the central nervous system.2a 
Other autoimmune disorders including systemic lupus 
erythematosus29 and rheumatoid arthritisJo have been found in 
families of autistic children. Autoantibodies to brain 
serotonin receptors in autistic subjects have also been 
reported.31 In other studies, evidence has been found for 
immune reactivity to neural-tissue. These include studies 
performed by Weizman et al.2 and Singh et al.,32 in which 
there was a lymphocyte response and formation of 
autoantibodies, respectively, to human myelin basic protein. 
Moreover, Plioplys et al.33 found the presence of 
autoantibodies to a different brain antigen, the 210K 
neurofilament. These same authors showed an abnormally 
increased percentage of OR-positive T-cells lacking IL-2 
receptors in 17 autistic patients.4 This finding of DR-
positive T-cells lacking IL-2 receptors in autistic patients 
was confirmed by Warren et al.34 and is a characteristic seen 
in autoimmune diseases. 
COMPLEMENT 
The complement activation system is one of many immune 
defense mechanisms that provides protection against pathogens 
via two pathways: the classical pathway and alterative 
pathway. Both pathways function in the extracellular fluid. 
The classical pathway consists of nine proteins that 
participate in a sequential cascade of reactions. Cl, the 
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first protein of the pathway, is activated by an antibody 
bound to a membrane surface. The actual sequence for the 
classical complement components is Cl-C4-C2-C3-C5-C6-C7-C8-C9 
(see Figure 1) . The first five components have enzymatic 
activity and are considered to be proenzymes (precursors of 
inactive form of enzyme). · The last four form a membrane 
attack complex (MAC) . This complex of proteins, the MAC, 
aggregates to form a hollow cylinder that is inserted into 
the membrane of the pathogen. This cylindrical complex 
functions by allowing cellular material to "leak" out and, 
more importantly, water to enter. The osmotic pressure 
causes cell lysis, destroying the pathogen. 
The alternative pathway differs from the classical 
pathway in one fundamental way: how the pathway is initiated. 
The alternative pathway is triggered by C3 spontaneously 
attaching to a membrane surface, to microbial agents, to IgA, 
or to IgG4. Again, a sequence of reactions takes place with 
additional complement components Factor B, Properdin, and 
Factor D. The remaining components of this pathway, CS 
through C9, are the same as for the classical pathway with 
the same result of cell lysis. Thus, the latter stages of 
each pathway are shared between both the classical and 
alternative pathways. The alternative pathway is part of the 
innate immune system that is nonspecific and active at all 
times. 
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Classical Alternative 
Pathway Pathway 
Cl B 
C3 
cs 
C6 
C7 
C8 
C9 
Forma.tion of membrane channels 
Fig. 1. Complement system pathways. 
DIFFERENCE BETWEEN C4A 
AND C4B 
C4A and C4B, the two major isotypes of C4, are encoded 
by two closely linked genes within the MHC. The two genes 
are nearly 98% homologous, and extensive polymorphism is 
observed at their respective loci. Each C4 locus produces 
10 
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one large peptide chain that undergoes posttranslation 
modifications, such as internal cleavage and the formation of 
disulfide bonds to yield tripeptide molecules. The three 
subunits of the molecule have been labeled alpha, beta, and 
gamma, the alpha being the largest and the gamma chain being 
the smallest. 
When a C4 molecule is activated (cleaved by C1s), a 
small fragment of the amino end of the a chain is cleaved 
off . Removal of this small fragment exposes two activation 
sites. One is involved in the binding complement protein C2, 
and the other is an unstable internal thioester bond. The 
latter is responsible for attaching the C4 molecule to a 
membrane (or antigen) surface and for the unique functional 
differences observed between C4A and C4B molecules. C4A 
appears to preferentially bind to amino-rich surfaces by 
forming amide linkages via hydrolysis of the thioester bond; 
C4B tends to form -ester linkages from hydrolysis of the same 
bond.35 This difference in avidity to distinct functional 
groups is believed to be responsible for the unique functions 
of C4A and C4B. For example, C4B is four times more 
hemolytic to sheep red-blood cells than C4A. This is likely 
due to a predominance of hydroxyl groups on the red blood-
cell surface and therefore the greater deposition of C4B on 
the membrane. Other functional differences between C4A and 
C4B may be similarly explained. 
FUNCTIONAL ROLE OF 
COMPLEMENT 
Although complement provides a defense mechanism by 
causing cell lysis, additional protection is accomplished 
through a process termed opsonization. Opsonization is a 
process in which foreign particles are "marked" for cellular 
uptake by fragments of complement components produced by 
enzymatic cleavage during activation of the complement 
pathways. The C3b and C4b complement fragments are referred 
to as opsonins, and when deposited on a cell surface act as 
ligands for phagocytic cells. This mechanism provides 
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enhanced phagocytic efficiency. Therefore, the clearance and 
elimination of potential pathogenic organisms are increased 
via opsonization. 
C4B NULL ALLELE AND 
AUTISM 
One of the primary objectives of this project is to 
provide data to suggest a possible association of a C4B null 
allele with autism. A null allele is a an allotype that does 
not produce a functional gene product. The null allele may 
not produce any gene product at all or may produce an 
inactive gene product. In earlier studies it is suggested 
that autistic patients have a higher incidence of a null 
allele at the C4B locus than patients without the disorder.l2 
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The presence of a C4B null allele constitutes a complement-
component deficiency and results in decreased serum levels of 
C4B protein. Low levels of any complement component may 
limit the defensive mechanism provided by the complement 
activation system. 
EXTENDED MBC HAPLOTYPES 
The major histocompatibility complex (MHC) is located on 
the short arm of human chromosome 6. Within this region of 
about three million base pairs lie many genes involved in the 
immune system (see Figure 2) . The combination of all alleles 
within the MHC determines the haplotype for the chromosome 
observed. Therefore, a person will normally have two 
haplotypes (one for each chromosome 6) . These genes have 
been categorized into three classes: I, II, III. From the 
centromere the MHC gene classes are arranged in the following 
order: MHC II-MHC III-MHC I . . Most MHC I and MHC II gene 
products are cell surface proteins. However, MHC III 
proteins are not directly associated with a cell membrane. 
MHC I gene functions involve processing and presentation of 
antigens (small peptides) to T-cells, primarily CD8+ T-cells. 
While MHC II genes also function in antigen processing and 
presentation, their interaction is primarily restricted to 
CD4+ T-cells. MHC III genes code for a variety of products 
and have a wide array of functions, including cytokine 
14 
signaling and complement function. The three class III genes 
studied in this project are C4A, C4B, and Bf. 
DR C4B C4B C2 BF B 
Centromere --1---//---1-----1----1----1---//---1-- Telomere 
Fig. 2. Simple schematic of the MHC on chromosome 6. 
An extended MHC haplotype is a fixed conserved region 
within the MHC usually defined by HLA-B (MHC II), complotype 
Bf,C2,C4A,C4B, and HLA-DR (MHC II) alleles.6 However, the 
conserved region may extend beyond these genes. Because 
these genes behave as if they are "fixed," they are inherited 
as a group, showing a lower frequency of crossing-over than 
expected. This phenomenon is referred to as linkage 
disequilibrium.6 
NBC-DISEASE ASSOCIATION 
Linkage disequilibrium is one of two distinguishing 
features of the MHC. The other is extensive genetic 
polymorphism. Extensive polymorphism is a possible selective 
advantage for survival and, conversely, there is a 
possibility of association of certain diseases with 
particular MHC profiles (HLA profile), or haplotypes. Many 
such associations have been identified. For example, it has 
been found that a person whose HLA profile includes HLA-B27 
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has an 87.4 times greater risk of developing Ankylosing 
spondylitis than a person without HLA-B27.36 This is a strong 
association. The most common extended haplotype studied to 
date is designated B8-SC01-DR3 and has been found to be 
associated with several disease conditions including 
generalized mysthenia gravis, IgA deficiency, and systemic 
lupus erythematosus.37 
The mechanism responsible for the association of a 
particular MHC profile and disease remains unclear. However, 
the MHC's central role in processing and presenting foreign 
antigens for elicitation of an immune response is a possible 
explanation. One possibility is that the MHC proteins are 
not able to adequately process a pathogen and thereby 
activate necessary mechanisms for a host to mount an immune 
response. This inability of the host to defend itself 
immunologically would allow the pathogen to cause sufficient 
damage to result in disease. 
MBC CLASS II BYPERVARIABLE 
REGIONS 
Of all human genes known, MHC genes are thought to 
exhibit the highest degree of allelic polymorphism. The MHC 
Class II complex consists of two peptide subunits termed 
alpha and beta. Together, the two subunits fold to form an 
"antigen binding groove" where fragments of foreign proteins, 
6 to 25 amino acids long, are loaded following degradation 
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processes.38,39 These degraded fragments then act as antigens 
when presented in conjunction with MHC molecules to T-cell 
receptors. Most T-cells can only respond to antigens 
presented in this fashion. This is the commonly known 
phenomenon of MHC restriction. 
Interestingly, in allelic variants of HLA-DR molecules, 
nearly all the polymorphisms are contributed by the beta 
subunit,40 most of which lie in three areas termed the 
hypervariable regions (HVRs) . Correlation of polymorphic 
sites to the tertiary structure of the HLA-DR molecule is 
evident of an assignment of the hypervariable regions to the 
antigen-binding groove of the MHC complex.41 This implies 
that the antigenic fragment lying within the antigen-binding 
groove is in direct, or at least close, contact with the HVRs 
of the MHC subunits. The HVRs provide a crucial portion of a 
framework for the selective interaction of MHC molecules with 
antigenic peptides. 42 One ': antigenic . peptide may· bind to the 
antigen-binding groove with greater affinity than another 
peptide.43 Such selectivity determined by the HVR 
specificities of the HLA molecules is the essence of the 
strength and efficiency of an immune response.44 
HLA-DR allotypes can be further subtyped through 
analysis of amino acid sequences coded by the DRBl gene. 
More specifically, the heterogenicity of the HLA-DR4 subtypes 
can be traced to and identified by amino acid differences at 
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positions 37, 57, 67, 70, 71, 74, and 86 of the beta 
subunit.45 Based on sequence specificities, the subtypes are 
designated DRB1*0401, DRB1*0402, DRB1*0403, etc. The 
variations between subtypes may exist at one, two, or all 
three HVRs. 
Several research groups are studying potential roles HVR 
specificities may play in disease pathogenesis. Matsushita 
et al. noted that patients with methimazole-induced insulin 
autoimmune syndrome express the DRB1*0406 allele and not 
DRB1*0405 allele.46 The group performed binding assays in 
which a small peptide fragment of human insulin alpha chain 
bound with much greater affinity to DRB1*0406 than to 
DRB1*0405. The authors conclude that presentation of the 
small fragment by antigen-presenting cells may lead to 
activation of self-insulin-specific T-helper cells. Another 
study47 performed by Topham et al. looked at experimental 
autoimmune encephalomyelitis (EAE), which represents a mouse 
model for human multiple sclerosis. Mice were vaccinated 
with an 18-amino acid peptide from HVR3 of the mouse MHC 
class II beta chain. The treatment elicited auto-antibodies 
to the small beta peptide and aided in preventing and 
treating EAE. A similar avenue may be useful in the 
treatment of human autoimmune diseases associated with 
specific HVR sequences. 
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CHAPTER III 
MATERIALS AND METHODS 
SUBJECTS 
One hundred twenty-four subjects were included in this 
study; 45 autistic child subjects, 30 normal child subjects, 
and where possible, the parents of each participating child 
were also analyzed by the same methods. Diagnosis of 
infantile autism was made by using DSM-IIIR criteria as 
established by at least two psychiatrists or psychologists.16 
All subjects were of Northern European descent and were 
living in the same geographical area (Northern Utah) at the 
time of this study. In addition, all normal subjects were 
screened for possible autoimmune disorders (e.g., adolescent 
diabetes) . 
PLASMA PREPARATION 
Blood samples used in this study were collected via 
venipuncture following informed consent procedures. Freshly 
drawn samples were centrifuged at 2,000 rpm (900x g) for 10 
minutes. Plasma was stored at -7o·c until used. 
ELECTROPHORESIS OF C4A 
AND C4B 
Prior to electrophoresis, plasma samples were treated 
with two enzymes, Neuraminidase Type V and Carboxypeptidase B 
1 9 
Type II (both from Sigma, St. Louis, MO). Approximately 0.13 
units of neuraminidase were added to 10 ~1 of plasma and 
incubated for 18 hours at 4·c followed by 1 hour of 
incubation at 37"C. Approximately 1 to 1.3 units of 
carboxypeptidase B were added to each sample and incubated 
for 30 minutes at room temperature (=25.C). 
Agarose gels (SeaKem ME Agarose, FMC) were prepared with 
electrophoresis buffer (8 mM Barbital, 32 mM Sodium Barbital, 
37 mM Gylcine, and 19 mM Tris[hydroxymethyl]aminomethane)and 
distilled H2 0. Approximately 13 ml of liquified 0 . 7% agarose 
was loaded on the hydrophilic side of a 10-cm x 10-cm 
electrophoresis film (i.e. gel bond) to create a 1.3-mm thick 
gel. Sample wells were formed in the gel with the use of a 
15-well, 0.75-mm comb (BioRad, Hercules, CA). The gel was 
allowed to cool and solidify. 
The gel was placed on a cooling plate (Horizontal 
Electrophoresis Cell, BioRad, Hercules, CA) at 4·c with the 
wells near the cathode. Wicks were placed at both ends of 
the gel so as to bridge the buffer chambers and the gel. 
Four microliters of treated samples were loaded into each 
well. The same volume of sickle cell hemoglobin (HbS, Sigma, 
St. Louis, MO) was loaded in the two outermost wells. 
Electrophoresis was terminated when the HbS markers migrated 
7 em anodally (about 3 hours) . Electrophoresis was performed 
at 400 constant volts while limiting the. current at 200 rnA 
and the power at 200 W. 
IMMUNOFIXATION AND 
STAINING OF C4 
Following electrophoresis, the gel was removed from the 
refrigerated plate, and 0.5 ml of a 3:2 dilution of anti-
human C4 antibody and distilled water (Atlantic Antibodies, 
Stillwater, MN) was spread on the surface of the gel {about 
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5~1/cm2). The gel was placed in a humidified box for 2 hours 
at room temperature. The antibody diffused into the gel and 
bound to C4 present to form a large antigen-antibody complex. 
This process is referred to as immunofixation because the 
antigen-antibody complex becomes insoluble and is immobilized 
within the gel. 
When immunofixation was complete, filter paper (Whatman 
No.5) was placed over the gel with light pressure to absorb 
excess or unbound antibody. The gel was then placed in 1X 
phosphate buffered saline solution (PBS, 1.9 mM sodium 
phosphate monobasic, 8.1 mM sodium phosphate dibasic, 154 mM 
sodium chloride, pH 7.4) overnight so any protein not bound 
by the anti-human C4 antibody could diffuse out of the gel. 
Therefore, only the complexed C4 protein remained in the gel. 
The next day the PBS was replaced with fresh PBS twice, one 
hour for each change. 
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Next, the gel was dried with a hair dryer. The dried 
gel was placed in a staining solution (1% Coomassie Brilliant 
Blue G-250, J.T. Baker) for 10 minutes, then in a destaining 
solution until the background was clear compared to the 
stained bands. The gel was preserved by rinsing in a 10% 
glycerol solution and dried again using a hair dryer. At 
this point blue "spots," or bands, may be visualized within 
the gel. These bands represented various C4 alleles and were 
used for designating specific C4 allotypes for each patient. 
C4 ALLOTYPING 
C4 allotyping, or complotyping, is based on the relative 
migration rates of C4A and C4B. C4A3 and C4B1 are the most 
common C4 allotypes in humans.48 The distance between these 
two bands is taken as a standard of unity. Where a band is 
located relative to the band positions of C4A3 and C4B1 
determines its designated allotype. The appearance of a 
single faded or weak band strongly suggests the presence of a 
C4 null allele. The presence of a null allele can be 
supported by a corresponding faded band in the plasma of one 
of the patient's parents. Also, the patient's measured C4 
protein serum level is expected to be low or moderately low. 
A patient with one C4B null is considered heterozygous for 
the C4B gene. If no C4B bands are visualized, the patient 
likely has two C4B null alleles and is considered homozygous 
for the gene. 
PREPARATION OF CELLS FOR DNA 
EXTRACTION 
Ten milliliters of venous whole blood were layered over 
4 ml Histopaque 1077 (Sigma, St. Louis MO) and centrifuged 
for 20 minutes at 1,000x g. Human peripheral blood 
mononuclear cells (PBMC), located at the top of the 
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Histopaque solution (i.e. at the interface), were transferred 
to a 15-ml conical bottomed tube, and the volume was brought 
to 10 ml with RPMI-1640 (Gibco Lab, Grand Island, NY) . The 
tube was centrifuged at 500x g for 10 minutes. The pellet 
was then resuspended in 5 ml RPMI-1640 and centrifuged a 
second time at 200x g for 5 minutes. Finally, the pellet was 
resuspended in 5 ml RPMI-1640 and 3 x 106 PBMCs were 
transferred into a 25-cm2 tissue culture flask containing 10 
ml HyQ Cyte L (HyClone Lab, Logan UT) and 1% 
phytohemaglutinin (PHA) (Gibco Lab, Grand Island, NY) . The 
flask was incubated for 5 days at 37·c. 
EXTRACTION OF DNA FOR FACTOR 
B TYPING 
After a patient's PBM's had proliferated to a 
concentration of 106 to 107 cells/ml (see above), the cultured 
solution was centrifuged at 2,000 rpm (900x g) for 10 
minutes. The supernatant was removed and 240 ~1 of lysis 
buffer (0.28 M sucrose, 10 mM Tris-HCL at pH 7.5, 5 mM MgC1 2 
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and 1% Triton X-100) and 18 ~1 of Pronase E (20 mg/ml, Sigma, 
St. Louis, MO) were added to the pellet and mixed well. This 
mixed solution was transferred to a microtube. 
Twelve microliters of .20% sodium dodecyl sulfate were 
added and the mixture was incubated at ss·c for 12 to 16 
hours (overnight) while shaking gently. An equal volume of 
phenol was added to the incubated mixture and vortexed for 15 
minutes followed by centrifugation, 14,000 rpm, for 10 
minutes. The aqueous layer was transferred to a separate 
microtube. Again, an equal volume of phenol was added 
followed by vortexing, centrifugation, and transfer of 
aqueous phase as mentioned above. An equal volume of 25:1 
chloroform:isoamyl alcohol was added to the transferred 
aqueous solution and vortexed for 15 minutes followed by 
centrifugation in a microcentrifuge at 14,000 . rpm (6,000x g) 
for 10 minutes. The aqueous phase (top layer) was 
transferred to a separate microtube. 
The DNA was precipitated by adding 0.1X volume of 3 M 
sodium acetate and 1.5X volume of isopropanol. The 
precipitated DNA was spooled onto the tip of a pasteur pipet 
and placed in 0.5 ml TE buffer (10 rnM Tris, 1 nM EDTA) to 
dissolve the DNA. A O.SX volume of 7.5 M ammonium acetate 
and 2X volumes ice-cold ethanol (100%) were added to the DNA 
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to reprecipitate it. The DNA was spooled. and placed into a 
fresh microtube. The ethanol was allowed to evaporate, and 
200 ~1 TE-4 buffer (10 nM Tris, 0.1 mM EDTA) was added to the 
sample. The DNA was dissolved overnight. DNA concentration 
was determined spectrophotometically at O.D. 260 nm and a 
measure of DNA purity was determined by obtaining a 260/280 
ratio. 
METHODS FOR TYPING FACTOR B 
The two methods used for allotyping of the Factor B gene 
(Bf gene) were polymerase chain reaction (PCR) and 
restriction fragment length polymorphism (RFLP) . For PCR, a 
50-~1 solution was prepared with the following reactants: 
patient's DNA (1 ~g/ml), 1.5 rnM MgC12 , 200 ~ deoxynucleotide 
phosphate bases, 1X PCR buffer (Promega Corp., Madison, WI), 
1 ~M of each primer (5'AAGTGATGTGGGTAGGACAGGC3' and 
5'TGCAGTCTGCCTTCCTGACAGTCT3'), and 2 units of Taq DNA 
Polymerase (Promega Corp., . Madison, WI). Finally, an equal 
volume of mineral oil was placed on top of the prepared 
solution to prevent evaporation. PCR was carried out for 30 
cycles in an Ericomp thermal cycler. Each cycle consisted of 
a 1-minute denaturation at 94"C, a 2-minute annealing at 
64"C, and 2-minute extension at 72"C. A 593-bp 
oligonucleotide PCR product was detected by agarose gel 
electrophoresis. Four microliters of the PCR product and 2 
~1 of tracking dye (50% glycerol, 0~25% bromophenol blue, 10 
mM EDTA) were combined and loaded onto a 2% NuSieve Agarose 
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(FMC Bioproducts, Rockland, ME) gel in a 1X Tris acetate 
buffer (0.04 M Tris-acetate, 0.001 M EDTA, 0.5 ~g/ml ethidium 
bromide) . A DNA size marker (1 Kb DNA ladder, Gibco BRL, 
Gaithersburg, MD) was loaded in the gel to estimate the 
approximate the size of the PCR product and ensure proper 
amplification of desired DNA region. The gel was run at 100 
rnA for approximately 40 minutes. The gel was placed on a UV 
light transilluminator and the DNA was detected by 
fluorescence of ethidium bromide. Photographs of each gel 
were taken for ease of storing collected data. 
Samples with positive PCR amplification were analyzed 
for the Mspi RFLP of the BF gene. The PCR product was 
digested with the isoshizomers Mspi or Hpaii (Promega Corp., 
Madison, WI) in the· following manner. A 30-~1 reaction 
solution was prepared by combining 6 ~1 of the amplified 
product, 3 ~1 lOX buffer for enzyme, 3 units :of endonuclease, 
and 20.7 ~1 sterilized dH2 0. The solution was vortexed 
gently and placed in a 37•c waterbath overnight. Next, 10 ~1 
of tracking dye were added to each sample and loaded in a 4% 
NuSieve Agarose gel. The gel was loaded with 40 ~1 of sample 
per well. Again, a DNA size marker (lKb DNA ladder, Gibco 
BRL) . was also loaded along with samples. The buffer used was 
a lX Tris-acetate-EDTA buffer with ethidium bromide. 
Electrophoresis ran for 50 minutes limited at 100 rnA. 
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The DNA fragments were visualized on a transilluminator 
and photographs taken. The S allotype of the Bf gene 
contains an Mspi site that produces two fragments after 
digestion of approximately 400 and 200 bp. An uncut 600 bp 
fragment depicted an F allotype of the Bf gene. 
C4 ANALYSIS 
CHAPTER IV 
RESULTS 
27 
In Figure 3, an immunoelectrophoresis gel of treated 
plasma samples is depicted. The dark uppermost and lowermost 
bands are the reference C4A and C4B allotypes, respectively, 
which serve as reference points for C4 allotyping. The 
uppermost band is C4A3 and the lowermost band is C4B1. The 
distance between C4A3 and C4B1 is given a reference value of 
100. Where other C4 allotypes migrate with respect to C4A3 
and C4B1 determines its designated phenotype. Figure 4 is a 
RFLP electrophoresis gel for Factor B. Lane 1 is a DNA size 
marker. In lane 2 there is an endonuclease cut site on one 
chromosome, represented the 200bp and 400bp bands (S 
allotype), and the lack of the same endonuclease cut site on 
the other chromosome, represented by the 600bp band 9F 
allotype) . In lane 3 there is only the 600bp band (therefore 
homozygous F), while in lane 4 there are the 400bp and 200bp 
bands, but not the 600bp band (therfore homozygous S) . 
At least one C4B null allele was found in 22 of 45 (49%) 
autistic subjects (Figure 5) . However, only 16 (20%) of the 
79 normal subjects carried the same allele. This increase in 
the number of C4B null alleles found in the autistic subjects 
was statistically significant (p <0.001). Of the 21 autistic 
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Lane 1 2 3 4 5 
Fig. 3. Gel analysis of C4A and C4B phenotypes. 
Lane 1 2 3 4 
Fig. 4. RFLP analysis of Factor B. 
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Fig. 5. Percentage of autistic subjects, their parents, and 
unrelated healthy controls expressing a C4B null allele. 
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patients who did carry a C4B null allele, 8 carried an 
additional C4 null allele, C4A or C4B, on the homologous 
chromosome. A C4A null allele was carried on 20 of 45 (44%) 
of the autistic subjects and on 37 of 79 (47%) of the normal 
subjects. This was not found to be significant 
statistically. Although the importance is not known, two C4 
null alleles were never found to be carried on the same 
chromosome. 
The percentages of C4B and C4A null alleles of the 
-
parents of the autistic patients and controls are included in 
Figures 5 and 6, respectively. The purpose of including the 
parental data was to see if perhaps C4 null alleles were 
inherited more maternally or paternally. As can be observed 
from Figures 5 and 6, no such tendency is evident. However, 
if a child expressed a null allele, at least one parent also 
carried a null allele. 
The C4 allotypes of patients, autistic and nonautistic, 
carrying a C4B null allele are given in Table 1. No one 
allele was found to be significantly associated with a C4B 
null allele in the presence of autism. 
EXTENDED HAPLOTYPE ANALYSIS 
Ten different extended haplotypes (Table 2) were 
observed in this study of autistic and normal subjects 
randomly selected from the general Northern Utah population. 
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Fig. 6. Percentage of autistic subjects, their parents, and 
unrelated healthy controls expressing a C4A null allele. 
Table 1. C4 allotypes in patients with C4B null alleles 
Autistics (n - 21) Nonautistics (n - 6) 
0 1 2 3 4 5 6 0 1 2 . 3 4 5 
C4Aa 3 21 1 4 1 
C4Ab 7 11 1 2 1 4 1 
C4Bb 1 18 1 1 2 4 
a This is the C4A allotype found on the same chromosome as 
the C4B null allele. 
b These are the C4 allotypes found on the chromosome not 
carrying the C4B null allele. 
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Table 2. List of extended haplotypes observed in this study 
Class 
I 
B Bf 
7 s 
8 s 
13 s 
18 F1 
35 F 
44 s 
44 F 
57 s 
62 s 
65 s 
Class 
III 
C2 C4A 
c 3 
c 0 
c 3 
c 3 
c 3,2a 
c 3 
c 3 
c 6 
c 3 
c 2 
C4B DR 
1 5 
1 3 
1 7 
0 3 
0 1 
0 4 
1 7 
1 7 
3 4 
1+2 1 
Class 
II 
DRB1 
0501 
0301 
0701 
0301 
0101 
0401 
0701 
0701 
0401 
0101 
Abbreviation 
B7-SC31-DR15 
B8-SC01-DR3 
B13:-SC31-DR7 
B18-F1C30-DR3 
B35-FC(3,2)-DR1 
B44-SC30-DR4 
B44-FC31-DR7 
B57-SC61-DR7 
B62-SC33-DR4 
B65-SC2(1,2)-DR1 
a This designation denotes . a rare duplication ·of the C4A gene 
in which one allele is · expressed as C4A3 and the other allele 
as C4A2. With the extended haplotype B35-FC(3,2)-DR1 it has 
been shown that the gene duplication results from gene 
conversion of B to A. The extended haplotype B44-SC30-DR4 
has undergone a similar conversion but it is conventionally 
designated as B44-SC30-DR4 instead of B44-SC(3,3)0-DR4. 
These 10 extended haplotypes were expressed on 53 of 90 
(58.8%) (Table 3) chromosomes studied in the autistic 
patients. The same extended haplotypes were carried on only 
33 of 128 (25.7%) chromosomes of unrelated normal subjects. 
Also, mothers of the autistic children had an increased 
representation of extended haplotypes, 41 of 78, compared to 
that of the fathers, 31 of 78 (Table 3). Many extended 
haplotypes have been found to be associated with various 
diseases. Diseases known or suspected to be associated with 
the extended haplotypes found in this study are displayed in 
Table 4. 
The phenotypic frequencies of the extended haplotypes 
observed in this study are shown in Table 3. Of the 10 
extended haplotypes found in this study, only one B44-SC30-
DR4 was significantly increased (p <0.05). B44-SC30-DR4 was 
not represented in any of the 64 control subjects. 
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In addition to the s~gnificant representation of B44-
SC30-DR4, four autistic subjects had a fragment · of this 
extended haplotype including SC30-DR4 (Table 5) (i.e. the 
fragment SC30-DR4 includes the Class II and Class III regions 
of this extended haplotype and a different Class I region 
allele) . Thus, the extended haplotype B44-SC30-DR4, or a 
fragment thereof, is represented in nearly a third (29%) of 
the autistic subjects as compared to less than 2% of the 
unrelated healthy contr,ols, Moreover, 12 mothers of autistic 
Table 3. Frequency of extended MHC haplotypes in autistic 
subjects 
Total Maternal Paternal Healthy 
Ext. Haplotype n = 45 n = 39 n = 39 n = 64 
B44-SC30-DR4 9(20.0)a 8 (20.5)a 3 (7. 7) 0 (0) 
BX-SC30-DR4b 4 (8.8) 4 (10.3) 2 ( 5. 1) 1 ( 1. 6) 
B35-FC(3,2)0-DR1 2 ( 4 . 4) 0 (0) 3 (7.7) 1 ( 1. 6) 
B18-F1C30-DR3 2 ( 4 . 4) 1 (2. 6) 1 (2. 6) 0 (0) 
B62-SC33-DR4 2 ( 4. 4) 2 ( 5. 1) 2 ( 5 .1) 2 ( 3. 1) 
B44-FC31-DR7 7 ( 15. 5) 4 (10.3) 4 (10.3) 4 (6.2) 
B57-SC61-DR7 3 (6.7) 4 (10.3) 1 ( 2. 6) 2 ( 3. 1) 
B13-SC31-DR7 3 (6.7) 2 (5. 1) 1 (2. 6) 1 ( 1. 6) 
B65-SC2(1,2)-DR1 1 (2. 2) 1 (2. 6) 0 (0) 0 (0) 
B7-SC31-DR15 7 ( 15. 5) 6 (15.4) 6 (15.4) 5 ( 7. 8) 
B8-SC01-DR3 13(28.8) 9 (23.1) 8 (20.5) 17(26.6) 
a p <0.001 as compared to values from healthy controls. 
b Fragment of the B44-SC30-DR4 extended haplotype including 
SC30 and DR4 but with a HLA B marker other than 844. 
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Tab1e 4. List of extended haplotypes observed this study 
and their reported disease associations49 
Extended Haplotype Disease Associations 
B7-SC31-DR15 Multiple sclerosis, IgA deficiency 
B8-SC01-DR3 Generalized myasthenia gra~is, IgA 
deficiency, Systemic lupus erythematosus, 
Celiac disease 
B13-SC31-DR7 
Bl8-F1C30-DR3 
B35-FC(3,2)-DR1 
B44-SC30-DR4 
B44-FC31-DR7 
B57-SC61-DR7 
B62-SC33-DR4 
B65-SC2(1,2)-SR1 
Insulin-dependent diabetes mellitus 
HIV rapid progression 
Rheumatoid Arthritis (child onset), 
Feltys Syndrome 
Celiac disease, IgA deficiency 
IgA deficiency, Psoriasis 
Insulin-dependent . diabetes mellitus, 
Rheumatoid Arthritis 
IgA deficiency 
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Tab~e 5 . B44-SC30-DR4 in autism 
With With 
Subjects N B44-SC30-DR4 X-SC30-DR4a 
Autistics 45 
Mothers 39 
Fathers 39 
Family normal chromosomesd 39 
Unrelated controls 64 
9 (20.0)b 
9 (23.1)b 
3 (7.7) 
4 (10.3) 
0 (0.0) 
4 (8.8)c 
3 (7.7) 
2 (5.1) 
1 (2.6) 
1 (1.6) 
a Fragment of B44-SC30-DR4 with identical DR, DQ and 
complement alleles but with a different B region allele. 
b p <0.001 as compared to unrelated controls. 
c p <0.05 as compared to unrelated controls. 
d Chromosomes of parents not segregating to autistic child. 
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children carried B44-SC30-DR4 or its fragment. In all, · 18 of 
45 (40%) of the autistic subjects or their mothers carried 
B44-SC30-DR4 or its fragment. 
Seven of the autistic subjects in this study had one or 
more siblings also diagnosed with autism. Their extended 
haplotypes and those of their siblings are given in Table 6. 
Interestingly, five of these subjects carried an extended 
haplotype on both chromosomes, and a sixth subject carried an 
extended haplotype on one chromosome. Five autistic siblings 
or sets of autistic siblings shared one or both extended 
haplotypes expressed by the corresponding reference autistic 
subjects. One autistic subject (Subject 6 in Table 6) 
carried an extended haplotype not received by the autistic 
sibling, and one autistic subject (Subject 7) and sibling did 
not express any extended haplotypes at all. 
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Table 6. Sharing of extended haplotypes by autistic siblings 
Subject Sibling 1 Sibling 2 Sibling 3 
1. B8-SC01-DR3 B8-SC01-DR3 B8-SC01-DR3 B8-SC01-DR3a 
B13-SC31-DR7 B13-SC31-DR7 B13-SC31-DR7 None 
2. BX-SC30-DR4 BX-SC30-DR4 B8-SC01-DR3 B8-SC01-DR3 
B7-SC31-DR15 None B7-SC31-DR15 B7-SC31-DR15 
3. B44-SC30-DR4 B44-SC30-DR4 
B57-SC61-DR7 None 
4 . B35-SC(3,2)0-DR1 B35-SC(3,2)0-DR7 
B44-FC31-DR7 None 
5. B62-SC33-DR4 B62-SC33-DR4 
B44-FC31-DR7 B8-SC01-DR3 
6. B44-FC31-DR7 None 
None a Nonea 
7 . None None 
None None 
a Subject 1 had an fourth sibling who also inherited B8-SC01-
DR3 and whose other chromosome did not express an extended 
haplotype. 
b Chromosome carries B62-SC31-DR15-DRW52-DQ6, which is a 
fragment of B7-SC31-DR15 (Table 1) . 
CHAPTER V 
DISCUSSION 
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Two significant findings of this study include increased 
frequencies of the C4B null allele and the extended haplotype 
B44-SC30-DR4 among autistic patients. The actual 
relationship of either finding to autism is unknown, although 
numerous mechanisms can be imagined. One possibility is that 
the extended haplotype B44-SC30-DR4 carries a functionally 
silent C4B null allele. The products of the C4 _ genes are 
essential to the activation of other critical components of 
complement pathways that provide protection against viruses, 
bacteria, and other pathogens. Increased frequency of C4B 
null alleles has been reported in patients with scleroderma5o 
and schizophrenia.51 In addition, accelerated disease 
progression following seroconversion to HIV and certain 
manifestations associated with AIDS have been associated with 
C4 null alleles. C4B null alleles have also been found to be 
underrepresented in people 80 years of age or older. 52,53 
This underrepresentation implies that expression of a C4B 
null allele may have a deleterious effect on a person's long-
term survival. It is logical to conclude that a person 
without the complement defense mechanism may have a greater 
predisposition to disease by infectious agents. 
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A small subset of autistic patients in this study did 
not carry a C4 null allele but their mothers did. At first 
glance this may argue against an association of a C4 
deficiency with autism. However, it is plausible, in some 
cases, that the mother's immune defiency (i.e. having a C4 
null allele) may be sufficient to allow a pathogen to persist 
and cause damage to the fetus during gestation. 
Interestingly, Laitinen et al. found spontaneous abortions to 
be associated with C4 null alleles.S4 
The relevance of B44-SC30-DR4 to autism may be through 
the Class II markers expressed on this extended haplotype. 
This study found the Class II and III portions (-SC30-DR4) of 
B44-SC30-SR4 in 18 of 45 (40%) autistic subjects and/or 
autistic mothers. The Class II (DR and DQ) markers are 
intimately involved in binding and presenting degraded 
processed peptide antigens to T lymphocytes. Class II 
markers, with a peptide antigen ligand, interact with T-cell 
receptor (TCR) molecules, resulting in activation of the 
mature T lymphocyte. If the Class II-TCR peptide complex 
interaction occurs during maturation of the T cell in the 
thymus, two types of selection will take place: positive and 
negative selection.ss,s6 These selection processes allow T-
cells to differentiate into competent mature T lymphocytes. 
During intrathymic development, negative selection appears to 
eliminate T-cells specific for self peptides due to their 
potentially harmful effects. In the positive selection 
process, T-cell receptors that interact with self MHC 
molecules with appropriate affinity evade cell death. All 
other developing T-cells die. Both processes are necessary 
to acquire T-cell maturity, and both are intrinsic in 
creating a T-cell repertoire that is unique to an MHC 
haplotype of an individual. 
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Both the antigen selection and binding function of MHC 
molecules are potential mechanisms that may explain HLA 
disease associations. The specific role of either mechanism 
to any disease remains unknown. However, several models have 
been proposed to explain disease associations to MHC 
haplotypes.s? In the first model, it is suggested that the 
MHC molecule itself operates as a receptor for the pathogen 
or disease-causing agent. Therefore, the MHC specificity 
(i.e. an individual's haplotype) of an individual would 
determine a pathogen's ability to infect a host and cause 
disease. In the second model, it is proposed that antigenic 
fragments from foreign agents (or self peptides in the case 
of autoimmune diseases) are selectively bound, with extreme 
efficiency, into the antigen binding groove of a particular 
MHC molecule.sa Hence, only persons expressing that specific 
MHC molecule would be able to mount an immune response to 
that specific antigenic determinant of the disease-causing 
agent. 
· In another · hypothesis it is postulated that MHC-
associated diseases arise from molecular mimicry that exists 
between the MHC molecule and the pathogenic agent.S9,60 In 
this model it is suggested that antigenic similarities occur 
or are shared between an etiological agent and the MHC 
disease associated molecule . . Such similarities could result 
in an infection unchallenged because the host would lack 
those clones specific for MHC self-peptides that were 
eliminated during negative selection. In other words, the 
host would not have any T-cells able to recognize the 
infectious· agent. Alternatively, if MHC-derived peptides 
were not utilized during negative selection, antigenic 
similarities could provoke a strong immune response to self 
tissues causing considerable tissue damage. This model, in 
which antigenic similarities between a pathogen and MHC 
molecules are proposed, is also known as the shared epitope 
hypothesis. 61,62 In several :studi-es -molecular mimicry in 
disease states have been implicated.63 
Finally, in a fourth hypothesis it is proposed that it 
is the T-cell repertoire determined by the MHC profile of an 
individual that is critical to the pathogenesis of a disease. 
Certain TCR specificities may be necessary to induce 
pathogenesis of a particular disease. These required 
specificities may only be present in an individual with a 
specific HLA allotype. 
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A number of research groups are studying the 
hypervariable regions (HVRs) of HLA molecules in an effort to 
link specific sequences within these areas to disease states. 
The MHC antigen subtypes DRB1*0401 and DRB1*0101 have been 
associated with rheumatoid arthritis (RA) . 64,65 For RA, it is 
believed that the basis for such associations is the 
existence of an amino acid sequence that is common between 
the third HVR of the beta chain of the RA associated MHC 
,"illeles and an epitope of an infectious agent. 62,66 For 
example, one study of rheumatoid arthritis patients found 
croHs-reactivity between the Escherichia coli heat shock 
protein dnaJ and the DRB1*0401 molecule.59 The cross-
reactivity suggested an epitope shared by both proteins. 
Another study, also including rheumatoid arthritis patients, 
determined the existance of a highly homologous sequence 
between a DR4 molecule and an Epstein-Barr virus 
glycoprotein. 60 In both cases, the · sequence displaying 
homogenecity was located in the · third ·hypervariable region of 
the HLA molecule. Exactly how MHC molecules affect 
susceptibility to RA is not known; however, the HVRs of the 
MHC molecules may control the binding of a arthritogenic 
peptide . 67, 68 
Peptides from the third hypervariable region of MHC DR4 
alleles generally elicit immune responses in patients with RA 
and normal subjects as shown by Salvat et al.69 It may be 
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evident that MHC-derived peptides are not functional in the 
negative selection process in the thymus. However, in the 
same study the HLA DRB1*0401 allele was found to be tolerant 
in the same group of subjects, thus displaying a uniqueness 
of activity. The HLA DRB1*0401 subtype is that allele found 
in the extended haplotype B44-SC30-DR4. 
The findings in this study, increased frequencies of the 
extended haplotype B44-SC30-DR4 and the C4B null allele in 
autistic subjects, are evidence for a possible association 
-
between autism and the major histocompatibility complex. 
Further studies may provide an actual relationship 
responsible for this association. 
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